Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixin meglumine administration

Violative chemical residues in animal-derived food products affect food safety globally and have impact on the trade of international agricultural products. The Food Animal Residue Avoidance Databank program has been developing scientific tools to provide appropriate withdrawal interval (WDI) estimations after extralabel drug use in food animals for the past three decades. One of the tools is physiologically based pharmacokinetic (PBPK) modeling, which is a mechanistic-based approach that can be used to predict tissue residues and WDIs. However, PBPK models are complicated and difficult to use by non-modelers. Therefore, a user-friendly PBPK modeling framework is needed to move this field forward. Flunixin was one of the top five violative drug residues identified in the United States from 2010 to 2016. The objective of this study was to establish a web-based user-friendly framework for the development of new PBPK models for drugs administered to food animals. Specifically, a new PBPK model for both cattle and swine after administration of flunixin meglumine was developed. Population analysis using Monte Carlo simulations was incorporated into the model to predict WDIs following extralabel administration of flunixin meglumine. The population PBPK model was converted to a web-based interactive PBPK (iPBPK) framework to facilitate its application. This iPBPK framework serves as a proof-of-concept for further improvements in the future and it can be applied to develop new models for other drugs in other food animal species, thereby facilitating the application of PBPK modeling in WDI estimation and food safety assessment.

[1]  Malcolm Rowland,et al.  Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective , 2018, Clinical pharmacology and therapeutics.

[2]  R. Gehring,et al.  Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. , 2016, Journal of veterinary pharmacology and therapeutics.

[3]  Barbara A. Wetmore,et al.  Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments , 2018, Journal of Exposure Science & Environmental Epidemiology.

[4]  J. Riviere,et al.  Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues. , 1998, Journal of veterinary pharmacology and therapeutics.

[5]  K. Odensvik.  Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers. , 1995, Journal of veterinary pharmacology and therapeutics.

[6]  T. Maurer,et al.  A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions , 2015, CPT: pharmacometrics & systems pharmacology.

[7]  Harvey J Clewell,et al.  The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.

[8]  T. Eissing,et al.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals , 2016, Clinical Pharmacokinetics.

[9]  S. Jaiswal,et al.  Role of enterohepatic recirculation in drug disposition: cooperation and complications , 2016, Drug metabolism reviews.

[10]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[11]  R. Gehring,et al.  Pharmacokinetics of Mequindox and Its Marker Residue 1,4-Bisdesoxymequindox in Swine Following Multiple Oral Gavage and Intramuscular Administration: An Experimental Study Coupled with Population Physiologically Based Pharmacokinetic Modeling. , 2017, Journal of agricultural and food chemistry.

[12]  R. Gehring,et al.  A framework for meta-analysis of veterinary drug pharmacokinetic data using mixed effect modeling. , 2015, Journal of pharmaceutical sciences.

[13]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[14]  Rebecca A Clewell,et al.  Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. , 2002, Environmental health perspectives.

[15]  J Wojciechowski,et al.  Interactive Pharmacometric Applications Using R and the Shiny Package , 2015, CPT: pharmacometrics & systems pharmacology.

[16]  Walter Schmitt,et al.  Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.

[17]  Y. Hu,et al.  Pharmacokinetics of Flunixin Meglumine After Intravenous and Intramuscular Administration in Pigs , 2007 .

[18]  Robert G. Pearce,et al.  httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.

[19]  J. Thiry,et al.  Evaluation of flunixin meglumine pour-on administration on prostaglandin E2 concentration in inflammatory exudate after induction of inflammation in cattle. , 2017, Research in veterinary science.

[20]  Andrew Worth,et al.  Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications , 2017, Regulatory toxicology and pharmacology : RTP.

[21]  C. Maltecca,et al.  The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine. , 2014, Journal of veterinary pharmacology and therapeutics.

[22]  J. Fisher,et al.  Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults , 2016, PloS one.

[23]  G. Smith,et al.  Pharmacokinetics of flunixin meglumine in swine after intravenous dosing. , 2006, Journal of veterinary pharmacology and therapeutics.

[24]  Jim E Riviere,et al.  Guide to FARAD resources: historical and future perspectives. , 2017, Journal of the American Veterinary Medical Association.

[25]  M. Laurentie,et al.  A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime , 2017, Journal of veterinary pharmacology and therapeutics.

[26]  K. Odensvik,et al.  High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. , 1995, American journal of veterinary research.

[27]  Board on Agriculture.  The use of drugs in food animals , 2013 .

[28]  A. Craigmill.  A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. , 2003, Journal of veterinary pharmacology and therapeutics.

[29]  H. E. Buist,et al.  Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .

[30]  R. Gehring,et al.  Pharmacokinetics and tissue elimination of flunixin in veal calves. , 2016, American journal of veterinary research.

[31]  R. Gehring,et al.  Avoiding violative flunixin meglumine residues in cattle and swine. , 2017, Journal of the American Veterinary Medical Association.

[32]  Harvey J Clewell,et al.  Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.

[33]  Raymond S. H. Yang,et al.  Physiologically based pharmacokinetic (PBPK) models for lifetime exposure to PCB 153 in male and female harbor porpoises (Phocoena phocoena): model development and evaluation. , 2010, Environmental science & technology.

[34]  Yu-Mei Tan,et al.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  Q. Zheng,et al.  Comment on: “A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood” , 2015, Clinical Pharmacokinetics.

[36]  Hea‐Young Cho,et al.  Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model , 2018, Archives of Toxicology.

[37]  J. Riviere,et al.  Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. , 2005, American journal of veterinary research.

[38]  Z. Zeng,et al.  Use of a Monte Carlo analysis within a physiologically based pharmacokinetic model to predict doxycycline residue withdrawal time in edible tissues in swine , 2012, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[39]  Weihsueh A. Chiu,et al.  Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling , 2018, Front. Pharmacol..

[40]  J. Fisher,et al.  A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.

[41]  Harvey J Clewell,et al.  Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  Shiew-Mei Huang,et al.  Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates , 2018, Clinical pharmacology and therapeutics.

[43]  R. Gehring,et al.  Probabilistic Physiologically Based Pharmacokinetic Model for Penicillin G in Milk From Dairy Cows Following Intramammary or Intramuscular Administrations , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[44]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[45]  H. Kindahl,et al.  Pharmacokinetics and Pharmacodynamic Effects of Flunixin after Intravenous, Intramuscular and Oral Administration to Dairy Goats , 2003, Acta veterinaria Scandinavica.

[46]  Jim E Riviere,et al.  Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples. , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  J. Riviere,et al.  Tabulation of FARAD Comparative and Veterinary Pharmacokinetic Data , 2006 .

[48]  J. Coetzee,et al.  The pharmacokinetics of transdermal flunixin meglumine in Holstein calves. , 2016, Journal of veterinary pharmacology and therapeutics.

[49]  Jason T Chittenden,et al.  Assessment of penetrant and vehicle mixture properties on transdermal permeability using a mixed effect pharmacokinetic model of ex vivo porcine skin , 2016, Biopharmaceutics & drug disposition.

[50]  C. Liao,et al.  Assessing exposure risks for freshwater tilapia species posed by mercury and methylmercury , 2016, Ecotoxicology.

[51]  Kevin McNally,et al.  A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..

[52]  L. Tell,et al.  Use of population pharmacokinetic modeling and Monte Carlo simulation to capture individual animal variability in the prediction of flunixin withdrawal times in cattle. , 2013, Journal of veterinary pharmacology and therapeutics.

[53]  R. Gehring,et al.  Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. , 2015, Journal of pharmaceutical sciences.

[54]  J. Riviere,et al.  Comparison of ELISA and LC-MS/MS for the measurement of flunixin plasma concentrations in beef cattle after intravenous and subcutaneous administration. , 2013, Journal of agricultural and food chemistry.

[55]  R. Gehring,et al.  Effect of formulation and route of administration on tissue residues and withdrawal times. , 2005, Journal of the American Veterinary Medical Association.

[56]  W. Chou,et al.  Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification. , 2019, Environment international.

[57]  Zhoumeng Lin,et al.  Human Food Safety Implications of Variation in Food Animal Drug Metabolism , 2016, Scientific Reports.

[58]  J. Riviere,et al.  Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus) , 2014, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[59]  J. Riviere,et al.  Use of Probabilistic Modeling within a Physiologically Based Pharmacokinetic Model To Predict Sulfamethazine Residue Withdrawal Times in Edible Tissues in Swine , 2006, Antimicrobial Agents and Chemotherapy.

[60]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[61]  Anna K. Johnson,et al.  Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration , 2013, BMC Veterinary Research.

[62]  Frédéric Y Bois,et al.  Physiologically based modelling and prediction of drug interactions. , 2010, Basic & clinical pharmacology & toxicology.

[63]  P. Toutain,et al.  Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed‐effects to characterize and quantify variability in drug pharmacokinetics , 2018, Journal of veterinary pharmacology and therapeutics.

[64]  G. Smith,et al.  Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. , 2012, Journal of dairy science.

[65]  M. Roberts,et al.  Mathematical Models for Topical and Transdermal Drug Products , 2014 .

[66]  Brad Reisfeld,et al.  Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[67]  Jeffrey W Fisher,et al.  Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. , 2015, Toxicology and applied pharmacology.

[68]  M. Shimoda,et al.  Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver. , 2004, Journal of veterinary pharmacology and therapeutics.

[69]  R. Gehring,et al.  Development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle for food safety assessment. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[70]  M. Sheffer,et al.  CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .

[71]  Stephanie Läer,et al.  A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows , 2015, Clinical Pharmacokinetics.

[72]  L. Musib,et al.  Pediatric Dose Selection and Utility of PBPK in Determining Dose , 2018, The AAPS Journal.

[73]  Yu-Mei Tan,et al.  Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[74]  B. Kukanich,et al.  The construction and application of a population physiologically based pharmacokinetic model for methadone in Beagles and Greyhounds , 2018, Journal of veterinary pharmacology and therapeutics.